Dexmedetomidine Analgesia Effects in Patients Undergoing Dental Implant Surgery and Its Impact on Postoperative Inflammatory and Oxidative Stress

Abstract EN

The aim of the study was to determine whether or not dexmedetomidine- (DEX-) based intravenous infusion in dental implantation can provide better sedation and postoperative analgesia via suppressing postoperative inflammation and oxidative stress.

Sixty patients were randomly assigned to receive either DEX (group D) or midazolam (group M).

Recorded variables were vital sign (SBP/HR/RPP/SpO2/RR), visual analogue scale (VAS) pain scores, and observer’s assessment of alertness/sedation scale (OAAS) scores.

The plasma levels of interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-α), antioxidant superoxide dismutase (SOD), and the lipid peroxidation product malondialdehyde (MDA) were detected at baseline and after 2, 4, and 24 h of drug administration.

The VAS pain scores and OAAS scores were significantly lower for patients in group D compared to group M.

The plasma levels of TNF-α, IL-6, and MDA were significantly lower in group D patients than those in group M at 2 h and 4 h.

In group M, SOD levels decreased as compared to group D at 2 h and 4 h.

The plasma levels of TNF-α, IL-6, and MDA were positively correlated with VAS pain scores while SOD negatively correlated with VAS pain scores.

Therefore, DEX appears to provide better sedation during office-based artificial tooth implantation.

DEX offers better postoperative analgesia via anti-inflammatory and antioxidation pathway.